title: Nilotinib-induced hyperbilirubinemia: is it a negligible adverse event?
authors.forename: Min Kyoung
authors.initials: MK
authors.lastname: Kim
authors.forename: Hee Soon
authors.initials: HS
authors.lastname: Cho
authors.forename: Young Kyung
authors.initials: YK
authors.lastname: Bae
authors.forename: Kyung Hee
authors.initials: KH
authors.lastname: Lee
authors.forename: Hae-Sun
authors.initials: HS
authors.lastname: Chung
authors.forename: Soo-Youn
authors.initials: SY
authors.lastname: Lee
authors.forename: Myung Soo
authors.initials: MS
authors.lastname: Hyun
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D014453:Glucuronosyltransferase / Q000235:genetics; D006579:Heterozygote; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced* / Q000235:genetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D000099148:UGT1A1 Enzyme
chemical_list: D000970:Antineoplastic Agents; D014453:Glucuronosyltransferase; D011743:Pyrimidines; D000099148:UGT1A1 Enzyme; C498826:nilotinib